Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5335-5349

  Maftouh, Mina ^a   Belo, Ana I ^a   Avan, Amir ^a,b   Funel, Niccola ^c   Peters, Godefridus J ^a   Giovannetti, Elisa ^a,c   van Die, Irma ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Galectin 4; Lymph node ratio; Migration; Pancreatic ductal adenocarcinoma; Primary PDAC cells; Wnt catenin pathway

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; GALECTIN 4; SURVIVIN; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN;

ADENOCARCINOMA CELL LINE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GAL 4 GENE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; BIOSYNTHESIS; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

AGED; BETA CATENIN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; PANCREATIC NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84906237957     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2104     Document Type: Article

References (44)

1. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M. Pancreatic cancer. Lancet. 2011; 378(9791):607-620.
2. Hidalgo M. New insights into pancreatic cancer biology. Ann Oncol. 2012; 23 Suppl 10:x135-138.
3. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-292.
4. Cummings RD and Liu FT. (2009). Galectins. Chapter 33: Cold Spring Harbor Laboratory Press).
5. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K and et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994; 76(4):597-598.
6. Yang RY, Rabinovich GA and Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008; 10:e17.
7. Danguy A, Camby I and Kiss R. Galectins and cancer. Biochim Biophys Acta. 2002; 1572(2-3):285-293.
8. Liu FT and Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005; 5(1):29-41.
9. Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM and Yu LG. Serum galectin-2,-4, and-8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 2011; 17(22):7035-7046.
10. Tang D, Zhang J, Yuan Z, Gao J, Wang S, Ye N, Li P, Gao S, Miao Y, Wang D and Jiang K. Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma. PLoS One. 2014; 9(3):e90476.
11. Kim SW, Park KC, Jeon SM, Ohn TB, Kim TI, Kim WH and Cheon JH. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. Cell Oncol (Dordr). 2013; 36(2):169-178.
12. Bauer A, Kleeff J, Bier M, Wirtz M, Kayed H, Esposito I, Korc M, Hafner M, Hoheisel JD and Friess H. Identification of malignancy factors by analyzing cystic tumors of the pancreas. Pancreatology. 2009; 9(1-2):34-44.
13. Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee K, Chen X, van de Rijn M and Brown PO. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS One. 2007; 2(3):e323.
14. Belo AI, van der Sar AM, Tefsen B and van Die I. Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells. PLoS One. 2013; 8(6):e65957.
15. Satelli A, Rao PS, Thirumala S and Rao US. Galectin-4 functions as a tumor suppressor of human colorectal cancer. International Journal of Cancer. 2011:n/a-n/a.
16. Clevers H and Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149(6):1192-1205.
17. Zhang Y, Morris JPT, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M and Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013; 73(15):4909-4922.
18. Hecht A, Vleminckx K, Stemmler MP, van Roy F and Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. Embo J. 2000; 19(8):1839-1850.
19. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM, Sutherland RL, Dlugosz A, Rustgi AK and Hebrok M. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One. 2007; 2(11):e1155.
20. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT and Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009; 13(7):1337-1344.
21. Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Wurdinger T and Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 2013; 73(22):6745-6756.
22. Delacour D, Gouyer V, Zanetta JP, Drobecq H, Leteurtre E, Grard G, Moreau-Hannedouche O, Maes E, Pons A, Andre S, Le Bivic A, Gabius HJ, Manninen A, Simons K and Huet G. Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells. J Cell Biol. 2005; 169(3):491-501.
23. Stowell SR, Arthur CM, Dias-Baruffi M, Rodrigues LC, Gourdine JP, Heimburg-Molinaro J, Ju T, Molinaro RJ, Rivera-Marrero C, Xia B, Smith DF and Cummings RD. Innate immune lectins kill bacteria expressing blood group antigen. Nat Med. 2010; 16(3):295-301.
24. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, Lam S, Gazdar AF and Laird-Offringa IA. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012; 22(7):1197-1211.
25. Oettle H, Neuhaus P, Hochhaus A and et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The conko-001 randomized trial. JAMA. 2013; 310(14):1473-1481.
26. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O'Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014; 32(6):504-512.
27. Belli C, Cereda S, Anand S and Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev. 2013; 39(5):518-524.
28. Kelloff GJ and Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2013; 11(3):201-214.
29. Volinia S and Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A. 2013; 110(18):7413-7417.
30. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009; 6(4):e1000046.
31. Huflejt ME and Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J. 2004; 20(4):247-255.
32. Paclik D, Danese S, Berndt U, Wiedenmann B, Dignass A and Sturm A. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One. 2008; 3(7):e2629.
33. Paclik D, Werner L, Guckelberger O, Wiedenmann B and Sturm A. Galectins distinctively regulate central monocyte and macrophage function. Cell Immunol. 2011; 271(1):97-103.
34. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13(1):11-26.
35. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR and Kahn M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A. 2004; 101(34):12682-12687.
36. Giovannetti E, Wang Q, Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, Vasile E, Peters GJ, Wurdinger T and Giaccone G. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014; 106(1):djt346.
37. Funel N, Giovannetti E, Del Chiaro M, Mey V, Pollina LE, Nannizzi S, Boggi U, Ricciardi S, Del Tacca M, Bevilacqua G, Mosca F, Danesi R and Campani D. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008; 88(7):773-784.
38. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ and Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012; 11(8):1735-1746.
39. Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ and Giovannetti E. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013; 19(5):940-950.
40. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ and Giovannetti E. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2014.
41. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A and Peters GJ. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer. 2011; 105(10):1542-1553.
42. Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Galla V, Sudo H, Falcone A, Campani D, Boggi U and Peters GJ. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012; 7(11):e49145.
43. Zhang D, Wang Y, Liang Y, Zhang M, Wei J, Zheng X, Li F, Meng Y, Zhu NW, Li J, Wu X-R and Huang C. (2014). Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration.
44. Wei Q, Eviatar-Ribak T, Miskimins WK and Miskimins R. Galectin-4 is involved in p27-mediated activation of the myelin basic protein promoter. J Neurochem. 2007; 101(5):1214-1223.